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Neonatal research evaluates many different outcomes using multiple measures. This can 
prevent synthesis of trial results in meta-analyses and selected outcomes may not be 
relevant to former patients, parents and health professionals.  
Objective 
To define a core outcome set (COS) for research involving infants receiving neonatal care in 
a high income setting. 
Design 
Outcomes reported in neonatal trials and qualitative studies were systematically reviewed. 
Stakeholders were recruited for a three-round international Delphi survey.  A consensus 
meeting was held to confirm the final COS, based upon the survey results. 
Participants 
414 former patients, parents, healthcare professionals and researchers took part in the 
eDelphi survey; 173 completed all 3 rounds. 16 stakeholders participated in the consensus 
meeting. 
Results 
The literature reviews identified 104 outcomes; these were included in round one.  
Participants proposed ten additional outcomes; 114 outcomes were scored in round two and 
three. Round one scores showed different stakeholder groups prioritised contrasting 
outcomes.  12 outcomes were included in the final COS: survival, sepsis, necrotising 
enterocolitis, brain injury on imaging, general gross motor ability, general cognitive ability, 
quality of life, adverse events, visual impairment/blindness, hearing impairment /deafness, 
retinopathy of prematurity and chronic lung disease/bronchopulmonary dysplasia. 
Conclusions and relevance 
A COS for clinical trials and other research studies involving infants receiving neonatal care 
in a high-income setting has been identified. This COS for neonatology will help standardise 
outcome selection in clinical trials and ensure these are relevant to those most affected by 
neonatal care.  
 
Database registration 




The neonatal period is crucial to long-term health and neonatal conditions are the leading 
cause of disability-adjusted life-year loss (1).  Preterm birth is a major cause of childhood 
morbidity (2, 3), and implicated in the pathogenesis of adult non-communicable diseases (4).  
Neonatal care is common; in high resource settings one in ten babies are admitted to a 
neonatal unit, a proportion that is increasing (5).   
 
Unfortunately there is a paucity of high quality evidence to guide much neonatal practice 
leading to variation in clinical care (6, 7) and outcomes (8, 9). One reason research fails to 
guide practice is because neonatal meta-analyses rarely provide conclusive 
recommendations (10, 11), commonly because trials have used heterogeneous, non-
comparable outcomes (12, 13).  A further limitation of neonatal and paediatric research is 
that the outcomes reported are frequently not meaningful to patients and parents (14, 15). 
 
One solution is the development of a core outcome set: important outcomes identified by key 
stakeholders using robust consensus methods (16).  A core outcome set could ensure all 
future research in a field reports a common subset of clinically meaningful outcomes and 
reduces research waste by facilitating meta-analysis (17).  A core outcome set is a minimum 
set and does not preclude researchers reporting other outcomes where relevant (16).  The 
use of core outcome sets for trials is promoted by journals (18), Cochrane Review Group 
editors (19) and research funders (20). Relevant, standardised outcomes are also crucial for 
observational research (21, 22), benchmarking (23), clinical audit (24) and quality 
improvement studies (25). 
 
OBJECTIVE  
To develop a core outcome set for research in neonatology.  
 
SCOPE 
The core outcome set has been developed to apply to all research involving babies receiving 
care on any neonatal unit in a high-income settings, with no limitation by gestational age at 
birth, birthweight or illness severity.  It is intended to apply regardless of the specific 
population of babies, clinical setting or clinical condition that a particular study addresses.  
The scope was established at the initial steering group meeting following direction from 
former patients and parents.  The parents and former patients all strongly expressed the 
view that “a sick baby is a sick baby”.  They were also clear that while it is possible to 
separate babies on a neonatal unit by gestation, weight or underlying diagnoses the 
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outcomes that are most important are universal to all.  Research involving babies cared for 
exclusively on labour or postnatal wards or in the community will be excluded as the majority 
are healthy needing little medical input.  
 
METHODS 
We prospectively registered the study with the Core Outcome Measures in Effectiveness 
Trials (COMET) initiative (Registration number 842) (26) and published the study protocol 
(27).  Research ethics approval was not required; the project involved consenting adults 
completing surveys (eFigure 1).  We formed a Steering Group to guide the core outcome set 
development comprising different disciplines, perspectives, and expertise (eText 1).   
 
We followed COMET initiative methodology (28) with reference to previous core outcome set 
development work (29).  We identified outcomes reported in neonatal trials and qualitative 




We undertook a prospectively registered systematic review to identify outcomes reported in 
neonatal clinical trials (30).  Randomised controlled trials are widely considered to be the 
most rigorous method to determine how a treatment affects patients (31, 32). We searched 
CENTRAL, CINAHL, EMBASE and Medline from July 2012 to July 2017.  Three authors 
(SA, SS, JW) independently double screened potentially relevant records based on titles and 
abstracts and reviewed the full text of selected studies to assess eligibility. Due to the large 
number of trials identified, only those with over 100 infants in each arm were included.  As 
many trials lead to more than one publication reporting outcomes at different time points we 
reviewed all linked publications.  Outcomes were extracted and categorised by physiological 
system. 
 
We undertook a second, prospectively registered (33), review to identify outcomes from 
qualitative research (34).  We searched ASSIA, CINAHL, EMBASE, Medline and PsycINFO 
from 1997 to 2017.  Publications describing qualitative data relating to neonatal care 
outcomes, reported by former patients, parents or healthcare professionals were included. 
Narrative text and grouped outcomes were thematically analysed by physiological system. 
 
The Steering Group assessed outcomes identified in the two reviews to produce a final 
inventory in which duplicated or closely related outcomes were grouped.  The inventory 





We recruited participants for the eDelphi from the following groups: 
• Former patients cared for on a neonatal unit, and parents of neonatal patients; 
recruited through neonatal charities and social media.  
• Nurses and allied health professionals (including neonatal nurses, midwives, speech 
and language therapists, occupational therapists and physiotherapists); recruited 
through professional journals and associations. 
• Doctors (including neonatologists, obstetricians, paediatric surgeons, general 
paediatricians, community paediatricians and general practitioners); recruited through 
the Royal College of Paediatrics and Child Health (RCPCH) and professional 
organisations.   
• Academics and researchers in the neonatal field; recruited through meetings, 
academic publications and organisations.  
 
Recruitment was international; participants had to have personal experience of neonatal 
care or research in a high-income setting.  We aimed for 30 participants in each group to 
achieve a total of 120 participants.  The sample size followed guidance (35) and previous 
core outcome set development (36). 
 
Consensus Process 
Participants completed a three round eDelphi survey (37) to establish consensus.  We ran 
the eDelphi using DelphiManager software (38).  To maximise response rates the survey 
was kept as short as possible (39) and extensive demographic data was not collected.  In 
each round we asked participants to rank outcomes between one and nine (with 1-3 
meaning ‘limited importance for decision making’ and 7-9 meaning ‘critical for decision 
making’) following GRADE guidelines (40) (Figure 1).  In round one, participants could 
suggest outcomes not identified in the reviews which they felt were important; these 
outcomes were included in rounds two and three.  After each round we collated the results.  
Before participants reviewed and re-scored outcomes in rounds two and three, we presented 
them with a bar chart showing how each outcome had been scored previously.  This graph 
amalgamated the scores from all stakeholder groups. We applied pre-defined consensus 
criteria to round three results (16).  Provisional core outcomes were those over 70% of 
participants in each group scored as ‘critical’ and less than 15% of each group scored as 
‘limited importance’.  Conversely, if over 70% of participants in each group scored an 
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outcome ‘limited importance’ and less than 15% in each group scored it ‘critical’ it was not 
included.  If neither criterion was met, an outcome was classified as ‘no consensus’.   
 
Consensus between groups 
We compared scoring patterns using the first round results to assess agreement between 
stakeholder groups.  Mean scores for each outcome were calculated for each group, 
pairwise comparisons were then made between groups.  Pearson’s correlation coefficient 
was calculated for each comparison; differences between coefficients was tested using 
Fisher’s r-to-z transformation (41). 
 
Attrition analysis 
We undertook an attrition analysis to ensure the eDelphi results had not been distorted by 
differences in opinion between those who dropped out and those who completed all surveys.  
We compared two groups: participants who only took part in round one (including those who 
dropped out during this round) and participants who contributed in all rounds.  We compared 
how these groups scored outcomes in round one. We used Mann-Whitney U to test for 
differences in scoring with Bonferroni correction for multiple comparisons (corrected to 5% 
significance).  For outcomes where a difference in scoring was identified we also tested if 
the different scoring patterns observed would have changed whether the outcome was 
considered ‘core’ in round one (according to the pre-defined consensus definition), 
suggesting attrition affected whether the outcome met the criteria for inclusion in the final 
core outcome set. 
 
Consensus meeting 
The final pre-specified phase was a face-to-face meeting to confirm the final core outcome 
set based upon the eDelphi results.  We only invited steering group members and eDelphi 
participants with additional expertise; the meeting was limited to 16 participants to facilitate 
discussion (42).  The consensus meeting remit was limited to refining the final survey 
results, no new outcomes were considered and the eDelphi results were paramount.  The 
consensus group were presented the results of the eDelphi and the attrition analysis.  They 
considered whether the identified core outcomes covered all necessary domains, whether 
there was overlap between outcomes and whether it would be feasible to expect all trials to 
record each outcome.  They discussed the following outcomes in depth: outcomes that met 
the consensus definition, ‘borderline’ outcomes that narrowly missed the consensus 
definition (defined as 70% of at least one stakeholder group scored the outcome as ‘critical’) 
and any the attrition analysis identified.  Meeting attendees discussed each outcome, then 
an anonymous vote was held on the question “should the outcome be included in the core 
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outcome set?”. For inclusion in the final set 70% of attendees had to vote “Yes”.  We have 
published the meeting minutes online (43).      
 
RESULTS 
This study was completed according to the study protocol (27).  The only deviation occurred 
during the review of trials: due to the large number of studies identified only trials with over 
100 neonates in each arm were included. The results of this core outcome set development 
are reported using COS-STAR reporting guidelines (44).  
 
In the review of clinical trials we identified 76 large neonatal trials reporting 216 outcomes, 
and in the qualitative literature review we identified 62 publications with 146 outcomes (34).  
The Steering Group reviewed these 362 outcomes, identified 19 duplicates and grouped 239 
closely related outcomes.  This resulted in a final inventory of 104 outcomes which were 
entered into the eDelphi (Figure 2) (full list in eTable 1).  Participants added ten additional 
outcomes following the first round (eTable 2). 
 
eDelphi surveys 
We recruited a total of 414 participants from 25 countries across 5 continents (eFigure 3).  
The distribution of participants in different stakeholder groups and their participation during 
the eDelphi is presented in Table 1.  Participation in all rounds exceeded our target of 120 
participants. 
 
Table 1 Stakeholder participation across eDelphi rounds 
Stakeholder Group Round 1 Round 2 Round 3 
Started Completed Started Completed Started Completed 
Parents and Patients 244 111 84 61 61 53 
Neonatal nurses and 
allied professionals 
53 44 39 38 34 33 
Doctors 83 74 71 62 67 59 
Neonatal researchers 34 31 29 26 29 28 
Total 414 260 223 187 191 173 
 
260 participants completed the first round.  Mean scores for parents and patients correlated 
with the scores of nurses and therapists more closely (r=0.83) than with the scores of 
doctors (r=0.51). The mean scores from doctors correlated most closely with those of 
researchers (r=0.96).  The differences between these correlations were statistically 
significant (p<0.01).  Pairwise comparisons are shown in Figure 3.  
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The final round was completed by 173 participants.  The highest scoring outcomes from 
each stakeholder group are shown in Table 2. 
 
Table 2 Highest scoring outcomes in round three by stakeholder group (outcomes ranked by 
mean score) 
Patients and parents Nurses and therapists Doctors Researchers 
Survival Survival Survival Survival 
Necrotising 
enterocolitis Necrotising enterocolitis Necrotising enterocolitis Necrotising enterocolitis 
Sepsis Harm due to treatment* Sepsis Sepsis 
Brain injury on imaging Sepsis Brain injury on imaging Visual impairment  
Harm due to treatment* Brain injury on imaging Hearing impairment  Hearing impairment 
Parental bonding with 
baby Quality of life 
Retinopathy of 
prematurity General cognitive ability 
Pain Visual impairment  General cognitive ability Quality of life 
Suffering Pain Harm due to treatment* Brain injury on imaging 
Parental involvement Suffering Ability to walk Breastfeeding 
Retinopathy of 
prematurity 
Parental bonding with 
baby 
General gross motor 
ability 
General gross motor 
ability 
*At the consensus meeting ‘Harm from medical treatment’ was re-defined as ‘Adverse 
events’ 
 
The pre-specified consensus definition was met for 15 outcomes; these were discussed at 
the consensus meeting along with 21 outcomes ranked as ‘borderline’.  The attrition analysis 
identified a statistically significant difference between scoring for 19 outcomes (eTable 3); for 
17 there was no difference in whether the outcome would have been included in the core 
outcome set.  The remaining two outcomes were discussed at the consensus meeting to 
ensure attrition had not distorted the consensus process. 
 
Consensus meeting 
At the consensus meeting 16 participants representing all stakeholder groups (5 former 
patients/parents, 3 nurses/therapists, 5 doctors, 3 researchers) discussed and voted on 
each of the 38 outcomes identified from the eDelphi results.  Twelve outcomes were 
identified for inclusion in the final core outcome set.  During discussion the outcome “Harm 
from medical treatment” was defined as “Adverse events” to allow better alignment with 
existing classifications of iatrogenic harm.  Two outcomes (“Retinopathy of prematurity” and 
“Chronic lung disease/bronchopulmonary dysplasia) relate only to preterm infants and 
should only be reported by trials involving this group. Meeting minutes and voting results are 




Core outcome set 
The final core outcome set comprises: 
1. Survival 
2. Sepsis 
3. Necrotising enterocolitis 
4. Brain injury on imaging  
5. Retinopathy of prematurity (preterm only) 
6. General gross motor ability 
7. General cognitive ability 
8. Quality of life 
9. Adverse events  
10. Visual impairment or blindness  
11. Hearing impairment or deafness  
12. Chronic lung disease/bronchopulmonary dysplasia (preterm only)   
(Outcomes ranked by percentage of Round 3 participants who scored each outcome ‘critical 
for decision making’) 
 
DISCUSSION 
Using robust, pre-registered consensus methodology we identified 12 outcomes to be 
reported in all future trials involving infants receiving care on a neonatal unit in a high-
income setting.  We hope use of this core outcome set will improve research quality and 
reduce waste.  The core outcome set is a minimum set of outcomes that are so important to 
all stakeholders that failing to report them will mean that important clinical uncertainties 
cannot be addressed, both at the level of individual studies and in subsequent meta-
analyses. 
 
This core outcome set complements the work by van‘t Hooft et al in which a core outcome 
set for interventions to prevent preterm birth was identified (45).  This contained maternal 
and neonatal outcomes but the scope was limited to antenatal interventions.  A number of 
core outcome sets have been developed in women’s health (36); in the newborn period 
these exist only for gastroschisis (46) and Hirschprung’s disease (47) with work underway 
for neonatal abstinence syndrome (48).  In rheumatology widespread adoption has led to full 
reporting of the rheumatoid arthritis core outcome set in 80% of relevant trials (49).  Similar 
uptake in neonatal research would reduce barriers to meta-analysis (10) and aid translation 




A strength of our project was the number of parents and former patients who took part.  Our 
review of trials found no reported involvement of parents or former patients in outcome 
selection; it is therefore unsurprising they that these groups report dissatisfaction with 
outcomes currently reported in neonatal research (14).  In our work former patients and 
parents scored outcomes by importance and could suggest additional important items.  Their 
priorities differed from other stakeholder groups, emphasising the importance of wide 
involvement in outcome selection.   
 
A limitation of our work was attrition during the eDelphi, which occurred despite efforts to 
optimise response rates (39). The attrition rates in this study are comparable with similar 
projects (36).  Explanations for the attrition include the wide range of outcomes (each survey 
took 20 minutes) and that participation was voluntary.  Former patients and parents were 
most likely to drop out; perhaps due to their caring commitments (50).  The attrition analysis 
identified outcomes where dropout could have skewed scoring patterns and distorted 
results; those identified were discussed further at the consensus meeting.  Participant 
attrition is common during Delphi surveys; steps to minimise attrition are evolving (51).  
Another limitation is that potential stakeholder groups were not represented (e.g. hospital 
administrators/policy makers).  No guidance mandates which groups should be involved in 
core outcome set development (16); our project included all groups included in most core 
outcome set development (52). 
 
Future work will standardise outcome measures and measurement time points for the 
outcomes identified.  While our review found outcome domains were similar across large 
neonatal trials, disparate measures and time points meant results were not comparable. 
Heterogeneity of measures and time points is a known barrier to evidence synthesis (12).  
Defining outcomes like ‘Adverse events’ or ‘Quality of life’, endpoints we have demonstrated 
to be important to all stakeholder groups, will allow research to report them consistently. 
Further input from former patients and parents is needed to ensure that outcome measures 
reflect their lived experiences (14). Starting in 2020 we will define measures and time points 
following OMERACT 2.0 methodology (53), in collaboration with other international efforts 
(54, 55).  Other core outcome sets have also been developed or are in development in the 
field of neonatology (46, 48): it is important that overlapping core outcome sets are 
harmonised to avoid the multitude of uncomparable outcomes being replaced by multiple 
incompatible core outcome sets.  The aim is that future research will report the core 
outcome set alongside trial specific outcomes; trial specific outcomes will address a 
particular research question and core outcomes will provide data for meta-analyses, 




While core outcome sets are associated with clinical trials, integration with routine data 
collection will reduce the burden on researchers, facilitate efficient research and improve 
quality.  This will ensure future audit, benchmarking and quality improvement projects are 
focused on outcomes important to all.  
 
CONCLUSION 
We have identified a core outcome set for neonatal research. Adoption of this set will 
standardise outcome selection and ensure these are relevant to those most affected by 
neonatal care. This will help research translate into improved clinical practice, optimising 
outcomes for neonatal patients. 
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What is already known on this topic? 
• Inconsistent reporting of outcomes of limited relevance to former patients, parents 
and healthcare professionals is an important cause of research waste. 
• There is a lack of evidence to guide many neonatal practices leading to variation in 
both the care provided and outcomes for patients. 
• Core outcome sets (agreed, standardised outcomes to be reported by all trials) have 
been developed in other fields to improve outcome selection and facilitate meta-
analysis. 
What this study adds? 
• Former patients, parents, doctors, nurses and researchers show differences in how 
they prioritise neonatal care outcomes.  
• We have identified twelve outcomes that are important to these stakeholders. 
• If these outcomes are reported in a standardised manner by all neonatal research 
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